Shore, ND, Powles, TB, Bedke, J, Galsky, MD, Redorta, JP, Ku, JH, Kretkowski, M, Xylinas, E, Alekseev, B, Ye, DW, Guerrero-Ramos, F, Briganti, A, Kulkarni, GS, Brinkmann, J, Calella, AM, Cesari, R, Eccleston, A, Michelon, E, Vermette, J, Wei, CM, Steinberg, GD. Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial. NATURE MEDICINE. 2025; 31(8)DOI:10.1038/s41591-025-03738-z. PMID:40450141. IF:50.000(Q1/1D).

Scilipoti, P, Moschini, M, Zaurito, P, Longoni, M, De Angelis, M, Afferi, L, Lonati, C, Tremolada, G, Viti, A, Santangelo, A, Pichler, R, Necchi, A, Montorsi, F, Briganti, A, Mari, A, Krajewski, W, Laukthina, E, Pradere, B, Del Giudice, F, Mertens, L, Gallioli, A, Soria, F, Gontero, P, Albisinni, S, Shariat, SF, Carando, R. Prognostic Implications of Patients With Clinically Node Positive Bladder Cancer Undergoing Radical Cystectomy. Clinical Genitourinary Cancer. 2025; 23(4)DOI:10.1016/j.clgc.2025.102377. PMID:40514269. IF:2.700(Q2/3D).

Sanguedolce, F, Tedde, A, Basile, G, Di Bello, F, Baboudjian, M, Uleri, A, Mancon, S, Chernysheva, D, Figuls, MR, Gallioli, A, Territo, A, Rouprêt, M, Palou, J, Breda, A. Prostate Cancer Outcomes in Immunocompromised Patients: A Systematic Review and Meta-analysis. European Urology Oncology. 2025; 8(4)DOI:10.1016/j.euo.2025.05.021. PMID:40533295. IF:9.300(Q1/1D).

Shore, ND, Powles, TB, Bedke, J, Galsky, MD, Redorta, JP, Ku, JH, Kretkowski, M, Xylinas, E, Alekseev, B, Ye, DW, Guerrero-Ramos, F, Briganti, A, Kulkarni, GS, Brinkmann, J, Calella, AM, Cesari, R, Eccleston, A, Michelon, E, Vermette, J, Wei, CM, Steinberg, GD. Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial (May, 10.1038/s41591-025-03738-z, 2025). NATURE MEDICINE. 2025; 31(8)DOI:10.1038/s41591-025-03894-2. PMID:40691368. IF:50.000(Q1/1D).